Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 502

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 502
---
0.23)   |     | -1.1, -0.2   |     |   0.009 |
| Average pain in lower back(2)                                     |                  | -0.7 (2.54)    |               | -0.2 (2.48)    |     | -0.5 (0.23)   |     | -0.9, 0.0    |     |   0.035 |
| PainDETECT(3)                                                     |                  | -2.7 (6.47)    |               | -2.5 (6.07)    |     | -0.3 (0.62)   |     | -1.5, 0.9    |     |   0.642 |
| Brief Pain Inventory – Short Form score (pain severity)(2)        |                  | -1.56 (1.952)  |               | -0.98 (1.928)  |     | -0.59 (0.200) |     | -0.98, -0.20 |     |   0.003 |
| Brief Pain Inventory – Short Form score (pain interference)(3)    |                  | -1.16 (2.413)  |               | -0.71 (2.095)  |     | -0.44 (0.221) |     | -0.87, 0.00  |     |   0.049 |

| (1) | Baseline NPRS score is the mean of at least five days and no more than seven days of scores from the screening visit until treatment randomization. For the current pain baseline is the last score prior to treatment. Baseline ODI is defined as the last ODI assessment score prior to the first dose on Day 1. |

| (2) | The analysis uses a REML-based MMRM with fixed effects for treatment (SP-102 or placebo), week, site, Pain Catastrophizing Scale group (<30 or ≥30), baseline score, and treatment-by-week interaction. |

| (3) | The analysis uses an ANCOVA model with fixed effects for treatment (SP-102 or placebo), site, Pain Catastrophizing Scale group (<30 or ≥30), and baseline score. |

ANCOVA: analysis of covariance; ANOVA: analysis of variance; BPI-SF:Brief Pain Inventory –